Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site

PHASE3CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

August 30, 2016

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2019

Conditions
Psoriatic ArthritisAxial SpondyloarthritisEnthesitis
Interventions
BIOLOGICAL

Secukinumab

Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4

DRUG

Secukinumab Placebo

Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks

Trial Locations (55)

1407

Novartis Investigative Site, Sofia

1413

Novartis Investigative Site, Sofia

4002

Novartis Investigative Site, Plovdiv

6000

Novartis Investigative Site, Stara Zagora

7700

Novartis Investigative Site, Targovishte

10128

Novartis Investigative Site, Torino

12435

Novartis Investigative Site, Berlin

14059

Novartis Investigative Site, Berlin

15706

Novartis Investigative Site, Santiago de Compostela

20100

Novartis Investigative Site, Milan

22391

Novartis Investigative Site, Hamburg

22415

Novartis Investigative Site, Hamburg

24128

Novartis Investigative Site, Bergamo

28040

Novartis Investigative Site, Madrid

28046

Novartis Investigative Site, Madrid

28942

Novartis Investigative Site, Madrid

29009

Novartis Investigative Site, Málaga

30161

Novartis Investigative Site, Hanover

30202

Novartis Investigative Site, Cartagena

32005

Novartis Investigative Site, Ourense

36001

Novartis Investigative Site, Pontevedra

36200

Novartis Investigative Site, Vigo

37134

Novartis Investigative Site, Verona

39104

Novartis Investigative Site, Magdeburg

39110

Novartis Investigative Site, Magdeburg

39300

Novartis Investigative Site, Torrelavega

40138

Novartis Investigative Site, Bologna

41009

Novartis Investigative Site, Seville

42105

Novartis Investigative Site, Wuppertal

44649

Novartis Investigative Site, Herne

48903

Novartis Investigative Site, Barakaldo

50937

Novartis Investigative Site, Cologne

54642

Novartis Investigative Site, Thessaloniki

55131

Novartis Investigative Site, Mainz

60528

Novartis Investigative Site, Frankfurt am Main

63800

Novartis Investigative Site, Brno

85100

Novartis Investigative Site, Potenza

91054

Novartis Investigative Site, Erlangen

92101

Novartis Investigative Site, Piešťany

140 59

Novartis Investigative Site, Prague

128 50

Novartis Investigative Site, Prague

686 01

Novartis Investigative Site, Uherské Hradiště

03042

Novartis Investigative Site, Cottbus

711 10

Novartis Investigative Site, Heraklion Crete

115 21

Novartis Investigative Site, Athens

115 27

Novartis Investigative Site, Athens

06800

Novartis Investigative Site, Mérida

TR1 3LJ

Novartis Investigative Site, Truro

E11 1NR

Novartis Investigative Site, Leytonstone

ST6 7AG

Novartis Investigative Site, Stoke-on-Trent

S75 2EP

Novartis Investigative Site, Barnsley

CW1 4QJ

Novartis Investigative Site, Cheshire

HU3 2JZ

Novartis Investigative Site, Hull

NW3 2QG

Novartis Investigative Site, London

NE29 8NH

Novartis Investigative Site, Tyne and Wear

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY